A Phase I/II Clinical Study of the KL003 Cell Injection in β-Thalassemia Major Participants

Transfusion-dependent Beta-Thalassemia Clinical Trial

Official title:

A Phase I/II Clinical Study Evaluating the Safety and Efficacy of KL003 Cell Injection in Transfusion-dependent β-thalassemia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06280378
• Other study ID #: CP-KL003-003/01
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: February 2024
• Est. completion date: May 2027

Study information

• Verified date: February 2024
• Source: Kanglin Biotechnology (Hangzhou) Co., Ltd.
• Contact: jingfeng Yan
• Phone: +86 18852138866
• Email: yanjingfeng[@]kanglinbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a non-randomized, open label, single-dose study in up to 41 participants with β-thalassemia major. The goal of this clinical trial is to evaluate the safety and efficacy of KL003 cell injection in subjects with β-thalassemia major.

Description:

This is a single-arm, multi-site, single-dose, Phase 1/2 study to assess KL003 Cell Injection in up to 41 participants with transfusion-dependent β-thalassemia (TDT) who are ≥3 and ≤35 years of age. KL003 Cell Injection is autologous CD34+ stem cells transduced Ex Vivo with a lentiviral Vector encoding βA-T87Q-Globin.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 41
• Est. completion date: May 2027
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 35 Years

Eligibility

Inclusion Criteria:

• Male or female age between 3-35 years;
• Diagnosis of transfusion-dependent ß-thalassemia and a history of at least 100 mL/kg/year of pRBCs or =8 transfusions of pRBCs per year for the prior 2 years;
• Karnofsky performance status =70 for participants=16 years of age; Lansky performance status of =70 for participants<16 years of age;
• Eligible to undergo auto-HSCT;
• Willing and able to follow the research procedures and conditions, with good compliance;
• Willing to receive at least the 2 years follow-up;
• Participant and/or legal guardians voluntarily participated in this clinical trial and signed the informed consent form.

Exclusion Criteria:

• Diagnosis of composite a thalassemia;
• Prior receipt of gene therapy or allo-HSCT;
• Meet the criteria for allo-HSCT and with an identified willing donor with full HLA match;
• Participants with severe iron overload at the time of screening;
• Presence of unusual antibody of red blood cell antigens or tested positive for platelet antibody;
• Known allergy to clinical trial drug (plerixafor or G-CSF or busulfan) or ingredient(DMSO etc.);
• Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the clinical investigator;
• Subjects positive with the following etiological tests: human immunodeficiency virus(HIV-1-2),human cytomegalovirus (HCMV-DNA),EB virus(EBV-DNA),HBV (HBsAg/HBV-DNA positive),HCV antibody (HCV-Ab), Human T-lymphotropic virus antibody (HTLV-Ab), Treponema pallidum antibody (TP-Ab);
• Uncorrectable coagulation dysfunction or history of severe bleeding disorder;
• History of major organ damage including:

1. Liver function test suggest AST or ALT levels >3× upper limit of normal(ULN);

2. Total serum bilirubin value>2.5×ULN;if combined with Gilbert syndrome, total bilirubin>3×ULN and direct bilirubin value>2.5×ULN;

3. Left ventricular ejection fraction <45%;

4. Baseline calculated eGFR<60mL/min/1.73m2;

5. Pulmonary function:FEV1/FVC<60% and/or diffusion capacity of carbon monoxide (DLco) <60% of prediction;

Related Conditions & MeSH terms

• beta-Thalassemia
• Thalassemia
• Transfusion-dependent Beta-Thalassemia

Intervention

Drug:
• KL003 Cell Injection Drug Product
Administered by intravenous infusion after myeloablative conditioning with busulfan.

Locations

Country	Name	City	State
China	Ruijin Hospital, Shanghai Jiaotong University School of Medicine	Shanghai	Shanghai
China	Institute of Hematology & Blood Diseases Hospital	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Kanglin Biotechnology (Hangzhou) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	KL003 engraftment	Proportion of participants with successful engraftment within 42 days after KL003 infusion.	From time of KL003 infusion through Month 2
Primary	Engraftment time of neutrophil and platelet	Neutrophil engraftment was defined as the first day when neutrophils = 0.5×10^9/L for 3 consecutive days; Platelet engraftment was defined as the first the first day of platelet count = 20.0×10^9/L for 7 consecutive days with no platelet transfusions.	From time of KL003 infusion through Month 24
Primary	Overall Survival	Overall survival was defined as time from date of KL003 infusion to date of death.	From time of KL003 infusion through Month 24
Primary	The number, frequency and severity of adverse events (AE) within 1 year after infusion of KL003 drug products	Frequency and severity of AEs & SAEs identified according to NCI CTCAE 5.0	From time of KL003 infusion through Month 24
Primary	Clonal dominance or secondary tumors caused by lentiviral vector insertional-mutation	Clonal dominance was defined as an ISA result greater than 90% of the total insertion sites (IS) at any time	From time of KL003 infusion through Month 24
Primary	Numbers of Participants With Vector-Derived Replication-Competent Lentivirus (RCL)	Peripheral blood samples were analyzed for detection of RCL	From time of KL003 infusion through Month 24
Secondary	The proportion of participants achieved Transfusion Independence (TI)for at least 6 months	TI 6 is defined as Hb = 90.0 g/L after reinfusion and without disease-related routine blood transfusion for 6 months	From time of KL003 infusion through Month 24
Secondary	The proportion of participants achieved TI 12	TI 12 is defined as Hb = 90.0 g/L after reinfusion and without disease-related routine blood transfusion for 12 months	From time of KL003 infusion through Month 24
Secondary	The start time of Transfusion Independence (TI) after KL003 infusion	The TI start time is defined as the first day of treated participants with transfusion-dependent ß-thalassemia (TDT) who achieved transfusion independence.	From time of KL003 infusion through Month 24
Secondary	Total Hb and the vector-derived HbA^T87Q	The total Hb is measured by routine blood test, Therapeutic globin expression was measured by HbA^T87Q in peripheral blood.	From time of KL003 infusion through Month 24